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STUDY QUESTION: Do genetic variations in the DNA damage response pathway modify the adverse effect of alkylating agents on
ovarian function in female childhood cancer survivors (CCS)?
SUMMARY ANSWER: Female CCS carrying a common BR serine/threonine kinase 1 (BRSK1) gene variant appear to be at 2.5-fold
increased odds of reduced ovarian function after treatment with high doses of alkylating chemotherapy.
WHAT IS KNOWN ALREADY: Female CCS show large inter-individual variability in the impact of DNA-damaging alkylating
chemotherapy, given as treatment of childhood cancer, on adult ovarian function. Genetic variants in DNA repair genes affecting ovarian
function might explain this variability.
STUDY DESIGN, SIZE, DURATION: CCS for the discovery cohort were identified from the Dutch Childhood Oncology Group
(DCOG) LATER VEVO-study, a multi-centre retrospective cohort study evaluating fertility, ovarian reserve and risk of premature
menopause among adult female 5-year survivors of childhood cancer. Female 5-year CCS, diagnosed with cancer and treated with
chemotherapy before the age of 25 years, and aged 18 years or older at time of study were enrolled in the current study. Results from the
discovery Dutch DCOG-LATER VEVO cohort (n¼ 285) were validated in the pan-European PanCareLIFE (n¼ 465) and the USA-based
St. Jude Lifetime Cohort (n¼ 391).
PARTICIPANTS/MATERIALS, SETTING, METHODS: To evaluate ovarian function, anti-Müllerian hormone (AMH) levels were
assessed in both the discovery cohort and the replication cohorts. Using additive genetic models in linear and logistic regression, five
genetic variants involved in DNA damage response were analysed in relation to cyclophosphamide equivalent dose (CED) score and their
impact on ovarian function. Results were then examined using fixed-effect meta-analysis.
MAIN RESULTS AND THE ROLE OF CHANCE: Meta-analysis across the three independent cohorts showed a significant interaction
effect (P¼ 3.0 104) between rs11668344 of BRSK1 (allele frequency ¼ 0.34) among CCS treated with high-dose alkylating agents
(CED score 8000 mg/m2), resulting in a 2.5-fold increased odds of a reduced ovarian function (lowest AMH tertile) for CCS carrying
one G allele compared to CCS without this allele (odds ratio genotype AA: 2.01 vs AG: 5.00).
LIMITATIONS, REASONS FOR CAUTION: While low AMH levels can also identify poor responders in assisted reproductive
technology, it needs to be emphasized that AMH remains a surrogate marker of ovarian function.
WIDER IMPLICATIONS OF THE FINDINGS: Further research, validating our findings and identifying additional risk-contributing
genetic variants, may enable individualized counselling regarding treatment-related risks and necessity of fertility preservation procedures in
girls with cancer.
STUDY FUNDING/COMPETING INTEREST(S): This work was supported by the PanCareLIFE project that has received funding
from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant
agreement no 602030. In addition, the DCOG-LATER VEVO study was funded by the Dutch Cancer Society (Grant no. VU 2006-3622)
and by the Children Cancer Free Foundation (Project no. 20) and the St Jude Lifetime cohort study by NCI U01 CA195547. The authors
declare no competing interests.
TRIAL REGISTRATION NUMBER: N/A.
Key words: ovarian reserve / childhood cancer / survivorship / fertility / gonadotoxicity
Introduction
Advances in childhood cancer treatment have increased cancer survival
rates leading to a growing population of childhood cancer survivors
(CCS) (Trama et al., 2016). Abdominal-pelvic radiotherapy and alkylat-
ing agents may compromise ovarian function (Green et al., 2009;
Overbeek et al., 2017; van der Kooi et al., 2017) and reduce survivors’
reproductive window. This may manifest as sub- or infertility (Chow
et al., 2016; Anderson et al., 2018) and a higher risk of premature
menopause (Levine et al., 2018), which in turn may impair quality of
life (Langeveld et al., 2004; van den Berg et al., 2007; Duffy and Allen,
2009; Carter et al., 2010; Zebrack et al., 2013; van der Kooi et al.,
2019a). Substantial inter-individual variability in the impact of treatment
on ovarian function in similarly treated CCS suggests a role for genetic
factors in modifying the association between treatment and the risk of
ovarian impairment.
Large-scale genome wide association studies (GWAS) in the general
population have identified single-nucleotide polymorphisms (SNPs) as-
sociated with age at natural menopause or premature ovarian insuffi-
ciency (POI) (Perry et al., 2009; Stolk et al., 2009; He et al., 2010;
Perry et al., 2013; Day et al., 2015, 2017). These SNPs include variants



































































































associated with the DNA damage response (Perry et al., 2013).
Alkylating agents, common chemotherapeutic agents used in childhood
cancer treatment, induce apoptosis of cancer cells by damaging DNA
and inhibiting cellular metabolisms, DNA replication and transcription
(Guainazzi and Schärer, 2010; Kondo et al., 2010; Fu et al., 2012). We
hypothesized that girls and young women with less efficient DNA
damage response systems are more vulnerable to the adverse effects
of alkylating agents leading to ovarian dysfunction later in life compared
to women with a fully efficient DNA damage repair system.
Serum levels of anti-Müllerian hormone (AMH), produced by the
granulosa cells of small growing follicles in the ovaries, are related to
age at onset of menopause in healthy women (van Disseldorp et al.,
2008) and can detect ovarian dysfunction prior to both detectible
changes in FSH/LH or oestrogen and clinical manifestations of meno-
pause (van Beek et al., 2007; Nelson et al., 2011; Anderson et al.,
2012; Dewailly et al., 2014). In addition, AMH has been demonstrated
as a useful and early surrogate marker of reduced ovarian function in
cancer survivors (van Beek et al., 2007; Lie et al., 2009; Charpentier
et al., 2014; Lunsford et al., 2014; van den Berg et al., 2018; van der
Kooi et al., 2019b).
Identifying genetic risk factors for treatment-related reduced ovarian
function may have clinical implications for risk assessment and medical
decision-making regarding fertility preservation in newly diagnosed girls
with cancer (van den Heuvel-Eibrink et al., 2018). The aim of the cur-
rent study was, therefore, to evaluate whether SNPs in the DNA
damage response pathway modify the adverse effect of alkylating
agents on ovarian function in CCS.
Materials and methods
Study participants—discovery cohort
CCS for the discovery cohort were identified from the Dutch
Childhood Oncology Group (DCOG) LATER VEVO-study, a multi-
centre retrospective cohort study evaluating fertility, ovarian reserve
and risk of premature menopause among adult female 5-year survivors
of childhood cancer (Overbeek et al., 2012). Data on prior cancer di-
agnoses and treatments were collected from medical files and informa-
tion on use of hormones (contraceptives or hormonal replacement
therapy) and menopausal status at time of study was obtained from
the DCOG LATER VEVO-study questionnaire (Overbeek et al.,
2012). The study was approved by the Medical Ethics Review
Committee (IRB protocol number 2006/249, VUmc) and written in-
formed consent was obtained from all participants.
Inclusion and exclusion criteria
Female 5-year CCS, diagnosed with cancer and treated with chemo-
therapy before the age of 25 years, and aged 18 years or older at time
of study were enrolled in the current study. Eligible participants pro-
vided a blood sample to quantify AMH levels and extract DNA. Some
types of treatment are known to have an invariably extremely detri-
mental effect on ovarian function. Effects can be so absolute, that this
leaves little room for inter-individual variance of the chosen phenotype,
as a result of genetic susceptibility. To maximize the potential to de-
tect a role of genetic variation, we excluded survivors who received
treatments associated with extensive gonadal toxicity including alloge-
neic stem cell transplantation, total body irradiation, bilateral ovary-




PanCareLIFE is a pan-European research project including 28 institu-
tions from 13 countries addressing ototoxicity, fertility and quality of
life (Byrne et al., 2018). This cohort included all adult 5-year female
survivors from the PanCareLIFE cohort who were treated for cancer
before the age of 25 years and fulfilled all inclusion criteria of this study
(van der Kooi et al., 2018). Demographic, disease- and treatment-
related data were collected from medical record files. Approval was
obtained from all relevant local review boards and written informed
consent from all participants.
St. Jude lifetime cohort
The St. Jude Lifetime Cohort Study (SJLIFE) is a cohort study among
10-year CCS in North America coordinated by the St. Jude Children’s
Research Hospital (Memphis, TN, USA) combining treatment data,
patient-reported outcomes and clinical assessment (Hudson et al.,
2017). Participants in SJLIFE who fulfilled the inclusion criteria and had
blood samples available for AMH and DNA analysis comprised the
second replication cohort. Sex hormone use at time of study was
documented.
Outcome and outcome definition
The outcome of this study was ovarian function, primarily determined
by serum levels of AMH. AMH levels of all three cohorts were deter-
mined in the endocrine laboratory of the Free University (VU) Medical
Center Amsterdam by an ultra-sensitive Elecsys AMH assay (Roche
Diagnostics GmbH, Mannheim, Germany) with an intra-assay coeffi-
cient of variation of 0.5–1.8%, a limit of detection (LoD) of 0.01mg/l,
and a limit of quantitation (LoQ) of 0.03mg/l (Gassner and Jung,
2014).
To account for age-dependency of AMH, participating women in
each cohort were divided into four age categories: 18–25; 25–32;
32–40; 40 years. These age cut-offs were chosen based on patient
numbers, driven by power among the groups, as well as clinical rele-
vance. In each cohort and for each age category, AMH was divided
into tertiles with exception of the last age category in which AMH lev-
els varied too little to adequately define tertiles. CCS with an AMH
level in the lowest tertile for their age category were defined as having
a reduced ovarian function (case), while those with an AMH-value in
the highest tertile for their age category were assumed not to have a
reduced ovarian function (control). Women over 40 years of age were
not considered a ‘case’ based on having an AMH-value in the lowest
tertile, but on whether or not they had reported a premature meno-
pause (absence of menses for >12 months before the age of 40) at
time of study. No ‘control’ subjects were defined in this age group
due to the inability to identify with sufficient certainty those without a
reduced ovarian function.































































































.Candidate gene variant selection
SNPs were selected based on a literature search of recently
published GWAS that identified loci associated with age at natural
menopause (Stolk et al., 2009; He et al., 2010; Perry et al., 2013;
van Dorp et al., 2013). Five GWAS hits in DNA damage response
pathways, specifically in the inter-strand cross-link repair pathway,
were selected based on the lowest P-value in the largest available
GWAS meta-analysis, with the hypothesis that polymorphisms in
these regions may increase the gonadotoxic effect of alkylating
agents. The selected polymorphisms were in UIMC1 (rs365132),
FANCI (rs1054875), RAD51 (rs9796), BRSK1 (rs11668344) and
MCM8 (rs16991615). Details concerning the genotype data and
quality control protocol are provided in the Supplementary materi-
als and methods file, sections ‘Quality protocol’ and ‘Linkage
disequilibrium’.
Alkylating agents
For each survivor, the administered cumulative dose of alkylating
agents was quantified using the validated cyclophosphamide equivalent
dose (CED) score (Green et al., 2014). To evaluate the effects of no,
low-, medium- and high-dose alkylating agent exposure, the CED
score was divided into four categories (0; >0–4000 mg/m2; 4000–
8000 mg/m2; 8000 mg/m2) (Green et al., 2014). Details on the ad-
ministered chemotherapeutics, CED score in categories and a frac-
tional polynomial selection procedure for CED score are further
discussed in the Supplementary Tables SI, SII, SIII, SIV and SV.
Statistical analyses
Additive genetic associations, with AMH levels based on imputed al-
lelic dosage, were evaluated by logistic and linear regression analyses
based on two models: (i) a main effect model; and (ii) an interaction
model. Both models evaluated the association between reduced
ovarian function and selected SNPs, adjusted for: ancestry and co-
hort effects using principle components, CED score (four categories
using CED of zero as the reference category) (Green et al., 2014),
use of sex hormones (replacement or contraception) at time of
study (yes/no), age at time of study (linear regression analysis only)
and imputed numbers (0–2) of the alternative allele of the investi-
gated variant (additive effects). The interaction model additionally in-
cluded an interaction term (SNP*CED category) for genetic variant
and CED score categories to evaluate the modifying effect of the
variant on the impact of CED score on low AMH levels. Results of
linear and logistic regression analyses are presented as regression
coefficients (beta) with SE and odds ratios (ORs) with a 95% CI. For
linear regression, AMH-levels were log-transformed to adjust for
the skewed residuals distribution. Sensitivity analyses performed to
assess the robustness of our findings, choices of the model and link-
age disequilibrium (Ward and Kellis, 2012) are shown in
Supplementary Table SVI. SNPs that showed an association with
log-transformed AMH levels or reduced ovarian function in either
model, or an interaction effect with CED (P-values < 0.05) were se-
lected for replication of both models. These analyses were
conducted using SPSS (Statistical Package for Social Sciences (SPSS)
version 24.0.0.1).
Replication and meta-analysis
Findings from the discovery cohort were evaluated in both replication
cohorts using identical models, except for sex hormone use at time of
study, which was only available in SJLIFE. Data of the discovery and
replication cohorts were combined and examined using meta-analytic
approaches, in R version 3.5.1, package ‘rmeta’ (R Development Core
Team, 2014), the overall P-values for interaction were meta-analysed
using Fisher’s method. Pooled estimates based on fixed-effects
meta-analysis are presented. In the meta-analysis, P-values <0.01
(0.05/5 gene variants, correcting for multiple testing) were considered
statistically significant. Finally, we calculated the cumulative ORs for ev-
ery genotype per CED category based on the prevalence of a reduced
ovarian function for every genotype and every CED category com-
pared to the prevalence of a reduced ovarian function for survivors
with a AA genotype treated without alkylating agents, to allow inter-
pretation of the findings.
Results
Discovery cohort
In total, 285 CCS from the DCOG LATER-VEVO cohort participated
in the current study (Table I). AMH levels per age category are
depicted in Table II. Allele frequencies of the investigated SNPs are
depicted in Table III. All SNPs were in Hardy–Weinberg equilibrium
(significance level <1*107). Results from logistic regression analyses
showed a negative association between BRSK1 (rs11668344) and re-
duced ovarian function (OR 0.56, 95% CI 0.35–0.90; P-value ¼ 0.016)
in the main effect-model. In addition, a non-significantly modifying ef-
fect of BRSK1 (rs11668344, minor allele frequency 0.34) on the effect
of CED 8000 mg/m2 on reduced ovarian function (OR 5.02, 95% CI
0.76–33.08; P-value ¼ 0.09) (Table III) was observed in the interaction
model. A significant modifying effect of a polymorphism in FANCI
(rs1054875) on the effect of CED in the category >0–4000 mg/m2
(OR 9.93, 95% CI 2.35–41.98; P-value ¼ 0.002) was also observed
(Table III). Sensitivity analyses of the main analysis did not change the
results (Supplementary Tables SVI and SVII). Linear regression analysis
showed a significant main effect of the BRSK1 gene variant, but not of
the other variants (Supplementary Tables SVIII and SIX). The two
SNPs within the BRSK1 and FANCI genes were assessed for replication
in the two replication cohorts.
Replication and meta-analysis
The PanCareLIFE and SJLIFE replication cohorts included 465 and 391
female CCS, respectively (Table I). Consistency of AMH across the
three cohorts is depicted in Table II. Table IV shows the combined
analysis of both replication cohorts and the final meta-analysis including
all three cohorts. Separate findings of the replication cohorts can be
found in Supplementary Tables SX and SXI. Full details of the meta-
analysis and its heterogeneity are described in Supplementary Tables
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Lifetime (n 5 391)
Age at time of study (years)
Median (range) 26.1 (18.3–52.4) 25.7 (18.0–45.0) 31.3 (19.1–59.5)
Age at diagnosis (years)
Median (range) 5.8 (0.3–17.8) 10.4 (0.0–25.0) 6.9 (0.0–22.7)
18–25 years 0 (0) 21 (4.5) 16 (4.1)
Time since diagnosis (years)
Median (range) 19.7 (6.7–41.4) 17.0 (5.0–39.1) 23.7 (11.0–46.2)
Diagnosis
Leukaemia 112 (39.3) 109 (23.4) 121 (30.9)
Lymphoma 49 (17.2) 154 (33.1) 70 (17.9)
Renal tumors 37 (13.0) 35 (7.5) 27 (6.9)
CNS tumors 3 (1.1) 12 (2.6) 28 (7.2)
Soft tissue sarcoma 23 (8.1) 31 (6.7) 28 (7.2)
Bone tumors 26 (9.1) 45 (9.7) 34 (8.7)
Neuroblastoma 11 (3.9) 35 (7.4) 36 (9.2)
Other 24 (8.4) 44 (9.6) 47 (12.0)
Radiotherapy
No 251 (88.1) 297 (63.9) 268 (68.5)
Yesa 34 (11.9) 170 (36.1) 123 (31.5)
Thorax 22 (7.7) 88 (18.9) 71 (18.2)
Abdomen (above pelvic crest) 3 (1.1) 12 (2.6) 30 (7.7)
Unilateral ovarianb 0 (0) 9 (1.9) 3 (0.8)
Other 20 (7.0) 61 (13.1) 51 (13.0)
CED score
0 106 (37.2) 161 (34.6) 198 (50.6)
>0–4000 mg/m2 80 (28.1) 103 (22.2) 21 (5.4)
4000–8000 mg/m2 52 (18.2) 68 (14.9) 78 (19.9)
8000 mg/m2 47 (16.5) 133 (28.6) 94 (24.0)
Hormone use at serum sampling
No 199 (69.9) 232 (49.9) 263 (67.3)
Yes 86 (30.1) 116 (24.9) 128 (32.7)
Oral contraceptive-free day 7 70 (24.6) 3 (0.6) NA
Anytime during oral contraceptive NA 94 (20.2) NA
HRT stop 7 2 (0.7) 20 (4.3) NA
Anytime, with intrauterine device 14 (4.9) NA NA
Unknown 0 (0) 117 (25.2) 0 (0)
Unilateral ovarian oophorectomy
No 284 (99.6) 463 (99.6) 391 (100.0)
Yes 1 (0.4) 2 (0.4) 0 (0)
AMH level
Median (range) 2.5 (<0.01–13.1) 2.1 (<0.01–18.5) 1.8 (<0.01–11.9)
Premature menopause (before age 40) and aged 40 years at study, 2 (0.7) NA 4 (1.0)
Values are represented as the number (%) of women, unless indicated otherwise.
aNot mutually exclusive.
bLikely in radiotherapy field.
AMH, anti-Müllerian hormone in mg/l; CCS, childhood cancer survivors; CED, cyclophosphamide equivalent dose; CNS, central nervous system; DCOG LATER-VEVO, Dutch
Childhood Oncology Group (DCOG) LATER VEVO cohort; HRT, hormonal replacement therapy; NA, not available; PanCareLIFE, PanCareLIFE cohort; St. Jude Lifetime, St. Jude
Lifetime Cohort.































































.SXII and SXIII, The overall P-value for interaction between
rs11668344 (BRSK1) and CED was 0.018. All three single-cohort anal-
yses suggest a consistent modifying effect for the G allele of
rs11668344 (BRSK1) on the effect of CED 8000 mg/m2 on reduced
ovarian function, although the relatively small-sized discovery cohort
did not reach significance for this association. The fixed-effects meta-
analysis showed an interaction effect of carrying the G allele of
rs11668344 in BRSK1 and an exposure to alkylating agents equivalent
to a CED score 8000 mg/m2 of 3.81 (95% CI 1.85–7.86,
P¼ 3.0 104), indicating that the odds of reduced ovarian function
increased with an increasing number of G alleles and CED
score 8000 mg/m2.Table V shows the ORs for any genotype per
CED category compared to female CCS with the AA genotype and
treated without alkylating agents. Female CCS who received alkylating
agents equivalent to a CED score 8000 mg/m2 had a 2.5-fold higher
odds of having an AMH serum level in the lowest tertile with one in-
stead of none G allele of rs11668344 in BRSK1 (genotype AG 5.00
(95% CI 3.27–7.63): AA 2.01 (95% CI 1.31—3.08)) and a 3-fold in-
creased odds with the genotype GG (OR 6.53 95% CI 2.36–18.05).
Linear regression analysis of BRSK1 showed inconsistent associations
with AMH in the two replication cohorts, and no significant association
was reached in the meta-analysis (Supplementary Table SXIII: beta
0.09, 95% 0.25–0.08). The modifying effect of >0–4000 CED in
FANCI (rs1054875) was non-significant in both replication cohorts, and
did not reach significance in the meta-analysis (OR 2.76, 95% CI 1.17–
6.53, P¼ 0.02) after correction for multiple testing.
Discussion
This is the first study to assess the influence of genetic factors on alky-
lating chemotherapy-induced reduced ovarian function, using AMH as
a biomarker, and incorporating two independent and identically phe-
notyped replication cohorts and a meta-analysis. We report a strong
modifying effect of a common SNP (minor allele frequency 0.34) in the
BRSK1 gene on the toxicity of high dose alkylating agents, resulting in a
2.5-fold increased odds of a reduced ovarian function for CCS carrying
one G allele compared to CCS without this allele and a 3-fold in-
creased odds for CCS carrying two G alleles.
One previous single-centre study evaluated the association between
ovarian function in CCS with SNPs associated with age at menopause
in the general population reporting that the T allele of rs1172822 of
the BRSK1 gene was inversely associated with serum AMH levels (van
Dorp et al., 2013). However, this study did not assess interaction be-
tween treatment and AMH levels or include validation using replication
cohorts. Recently, a SJLIFE GWAS study identified a haplotype associ-
ated with an increased risk of premature menopause, especially in the
subgroup of CCS who had received pelvic radiotherapy (Brooke et al.,
2018). However, the haplotype is beyond the scope of this study as
our population excluded survivors treated with bilateral ovarian radio-
therapy due to low inter-individual variation of POI and the haplotype
is not associated with DNA damage response genes.
The meta-analysis suggests a strong modifying effect of a G allele of
a genetic variant in BRSK1 (rs11668344 A>G) on alkylating agent-
related reduced ovarian function. The meta-analysis on reduced ovar-
ian function for the main effect of BRSK1, which is associated with an
earlier age at menopause in the general population (Stolk et al., 2009;
He et al., 2010; Perry et al., 2013), did not find a significant association
as the previous single-centre study reported (van Dorp et al., 2013).
Representing continuous variables such as CED-score in categories
may lead to increased type I error for the detection of interaction
effects (Royston and Altman, 1994). Supplementary analyses using
fractional polynomials (Supplementary Tables SIII, SIV and SV) show
that using the available data, estimating more flexible models to poten-
tially avoid these spurious findings, offers inconclusive results due to
lack of power, while not contradicting the results found using the pre-
defined categories.
............................................................................................................................................................................................................................
Table II AMH levels in tertiles by age categories.
VEVO PanCareLIFE St. Jude Lifetime
Age 18–25 n¼ 118 n¼ 209 n¼ 72
Lowest AMH tertile 1.08 (0.21–2.14) 0.66 (0.01–1.79) 1.48 (0.15–2.20)
Middle AMH tertile 3.07 (2.16–4.08) 2.51 (1.83–3.39) 2.79 (2.22–3.56)
Highest AMH tertile 5.37 (4.23–13.14) 4.98 (3.41–18.50) 4.91 (3.65–11.90)
Age  25–32 n¼ 102 n¼ 156 n¼ 143
Lowest AMH tertile 1.32 (0.01–2.14) 0.72 (0.01–1.49) 1.16 (0.01–1.84)
Middle AMH tertile 3.09 (2.15–4.59) 2.33 (1.52–3.26) 2.57 (1.98–3.57)
Highest AMH tertile 6.08 (4.65–12.76) 4.32 (3.27–9.08) 4.87 (3.58–10.48)
Age  32–40 n¼ 48 n¼ 89 n¼ 107
Lowest AMH tertile 0.36 (0.01–0.80) 0.05 (0.01–0.50) 0.51 (0.01–1.04)
Middle AMH tertile 1.33 (0.91–2.16) 1.19 (0.53–1.90) 1.69 (1.05–2.10)
Highest AMH tertile 3.65 (2.19–9.44) 3.42 (1.93–13.50) 3.27 (2.14–7.70)
Age  40 n¼ 17 n¼ 11 n¼ 69
No tertiles 0.16 (0.01–1.85) 0.47 (0.01–8.89) 0.09 (0.01–8.73)
Values are represented as the median (minimum–maximum), unless indicated otherwise.
VEVO, DCOG-LATER VEVO cohort.
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Table III Association of single nucleotide polymorphisms with reduced ovarian function and CED-score in DCOG LATER-
VEVO discovery cohort.
Gene Variant Chrom Ref. Alt. MAF Model Variant, interaction term OR (95% CI) P-value
BRSK1 rs11668344 19 A G 0.34 1 rs11668344 0.56 (0.35–0.90) 0.016
CED: 0 1 (ref) 0.001
– >0–4000 1.43 (0.65–3.11) 0.374
– 4000–8000 4.74 (1.92–11.71) 0.001
– 8000 5.04 (1.66–15.30) 0.004
Hormones 2.02 (1.00–4.07) 0.049
2 rs11668344 0.57 (0.25–1.31) 0.186
CED: 0 1 (ref) 0.133
– >0–4000 1.94 (0.62–6.07) 0.253
– 4000–8000 5.46 (1.32–22.66) 0.019
– 8000 1.91 (0.44–8.29) 0.386
SNP*CED: 0 1 (ref) 0.218
– >0–4000 0.66 (0.21–2.13) 0.489
– 4000–8000 0.85 (0.23–3.18) 0.807
– 8000 5.02 (0.76–33.08) 0.094
Hormones 2.01 (0.98–4.14) 0.058
FANCI rs1054875 15 A T 0.36 1 rs1054875 1.01 (0.61–1.67) 0.975
CED: 0 1 (ref) 0.001
– >0–4000 1.37 (0.63–2.95) 0.425
– 4000–8000 4.17 (1.73–10.05) 0.001
– 8000 4.98 (1.66–14.91) 0.004
Hormones 1.79 (0.91–3.54) 0.094
2 rs1054875 0.31 (0.11–0.90) 0.032
CED: 0 1 (ref) 0.009
– >0–4000 0.32 (0.10–1.06) 0.063
– 4000–8000 2.19 (0.60–7.95) 0.235
– 8000 3.71 (0.84–16.38) 0.084
SNP*CED: 0 1 (ref) 0.016
– >0–4000 9.93 (2.35–41.98) 0.002
– 4000–8000 3.49 (0.78–15.57) 0.102
– 8000 2.00 (0.38–10.44) 0.413
Hormones 1.83 (0.90–3.73) 0.095
MCM8 rs16991615 20 G A 0.08 1 rs16991615 0.90 (0.38–2.15) 0.817
CED: 0 1 (ref) 0.001
– >0–4000 1.37 (0.64–2.94) 0.420
– 4000–8000 4.16 (1.74–9.97) 0.001
– 8000 4.96 (1.65–14.87) 0.004
Hormones 1.80 (0.91–3.56) 0.089
2 rs16991615 0.85 (0.21–3.39) 0.820
CED: 0 1 (ref) 0.005
– >0–4000 1.36 (0.59–3.14) 0.473
– 4000–8000 4.48 (1.73–11.58) 0.002
– 8000 3.82 (1.22–11.95) 0.021
SNP*CED: 0 1 (ref) 0.973
– >0–4000 1.07 (0.14–8.06) 0.950
– 4000–8000 0.61 (0.05–6.74) 0.683
– 8000 NA NA
Hormones 1.89 (0.95–3.75) 0.069
(continued)





























..Rs11668344 is an intronic variant in THEM150B and an expression
quantitative trait locus that alters BRSK1 RNA gene expression in
whole blood (P-value ¼ 2.4 1019) (Westra et al., 2013) and has
regulatory histone marks, suggesting a regulatory function. Several
mechanisms for the modifying effect of BRSK1 on reduced ovarian
function in CCS can be considered. Alkylating agents are known to in-
duce apoptosis of cancer cells by damaging DNA and inhibiting cellular
metabolism, DNA replication and DNA transcription (Guainazzi and
Schärer, 2010; Kondo et al., 2010; Fu et al., 2012). We hypothesize
that due to a less efficient DNA damage response system, cancer
patients carrying the G allele of rs11668344 in BRSK1 are at an in-
creased risk of the DNA-damaging impact of alkylating agents in
healthy tissues most relevant to our outcome studied here, the ovary
(Fig. 1). It is plausible that the efficiency of the DNA damage response
system becomes crucial upon treatment with alkylating agents amount-
ing to high CED scores.
Future research will need to evaluate the relevant expression, which
we would expect in granulosa cells or the primordial follicle pool—as
opposed to the recruited and selected oocytes that have successfully
progressed towards maturation (see also Supplementary file ‘Biological
mechanism’).
The identification of this genetic risk factor for alkylating agents-
related low AMH levels, if confirmed for other measures of reduced
ovarian function, may improve future risk prediction models including
............................................................................................................................................................................................................................
Table III Continued
Gene Variant Chrom Ref. Alt. MAF Model Variant, interaction term OR (95% CI) P-value
UIMC1 rs365132 5 G T 0.5 1 rs365132 1.09 (0.70–1.69) 0.720
CED: 0 1 (ref) 0.001
– >0–4000 1.35 (0.63–2.91) 0.443
– 4000–8000 4.18 (1.75–10.00) 0.001
– 8000 5.03 (1.68–15.11) 0.004
Hormones 1.80 (0.91–3.54) 0.090
2 rs365132 0.79 (0.39–1.61) 0.518
CED: 0 1 (ref) 0.017
– >0–4000 0.44 (0.11–1.82) 0.257
– 4000–8000 4.05 (1.01–16.19) 0.048
– 8000 4.83 (0.78–29.90) 0.091
SNP*CED: 0 1 (ref) 0.265
– >0–4000 2.89 (0.93–8.98) 0.067
– 4000–8000 1.04 (0.32–3.39) 0.948
– 8000 1.01 (0.17–5.98) 0.988
Hormones 1.78 (0.89–3.57) 0.104
RAD51 rs9796 15 A T 0.42 1 rs9796 0.94 (0.62–1.44) 0.787
CED: 0 1 (ref) 0.001
– >0–4000 1.37 (0.64–2.94) 0.419
– 4000–8000 4.17 (1.74–9.99) 0.001
– 8000 4.98 (1.66–14.92) 0.004
Hormones 1.79 (0.91–3.53) 0.092
2 rs9796 0.92 (0.43–1.97) 0.838
CED: 0 1 (ref) 0.167
– >0–4000 1.66 (0.52–5.33) 0.397
– 4000–8000 4.33 (1.18–15.91) 0.027
– 8000 2.34 (0.48–11.42) 0.291
SNP*CED: 0 1 (ref) 0.546
– >0–4000 0.81 (0.28–2.33) 0.692
– 4000–8000 0.94 (0.29–3.16) 0.938
– 8000 2.82 (0.52–15.37) 0.230
Hormones 1.70 (0.85–3.39) 0.135
Alt, alternative allele; Chrom., chromosome; MAF, minor allele frequency; NA, not available; OR, odds ratio; Ref, reference allele; SNP, single-nucleotide polymorphism.
Position based on position build 37 on https://www.ncbi.nlm.nih.gov/snp/. Alt is reported as 0/1/2 (recalculated for presentation only, based on allelic dosage) for CCS with and
without reduced ovarian function (see Methods section for details). Model 1: adjusted for principal components, use of hormone use and CED-categories. Model 2: additional to
Model 1 interaction term of variant*CED category.


























..more adequate identification of groups with higher or lower risk of
chemotherapy-induced ovarian impairment. Upfront fertility preserva-
tion programs, including ovarian tissue cryopreservation, would benefit
from optimized prediction models as they can be directed to paediat-
ric cancer patients at highest risk for gonadotoxicity for whom the bal-
ance of benefits/drawbacks—including ethical considerations—is most
beneficial (Warren Andersen, 2018).
A major strength of this study is the inclusion of three independent
cohorts which enabled a meta-analysis. As there were some differen-
ces between the discovery and the replication cohorts, we performed
multiple sensitivity analyses to assess the choices of the model and co-
hort, which did not change our results. Another strength of this study
is the measurement of AMH levels, as a marker for reduced ovarian
function, with the same assay at one laboratory, eliminating between-
assay differences. Previous studies demonstrated that alkylating agents
are strongly associated with risk of reduced ovarian function as mea-
sured by decreased AMH levels in female CCS (Anderson et al., 2012;
Thomas-Teinturier et al., 2015; van der Kooi et al., 2017; van den
Berg et al., 2018). By using AMH levels as a marker of ovarian func-
tion, this study included a fairly substantial number of cases likely at
............................................................................................................................................................................................................................






(VEVO 1 PCL 1 SJLIFE)
meta-analysis
Gene Variant Ref>Alt Model variant,
interaction
OR (95% CI) Direction P-value OR (95% CI) Direction P-value
BRSK1 rs11668344 A>G 2 rs11668344 0.82 (0.54–1.24) þ 0.349 0.76 (0.53–1.11) þ 0.152
CED: 0 1 (ref) 5.5 104 1 (ref) 5.6 104
– >0–4000 0.58 (0.21–1.58)  0.284 0.98 (0.46–2.09) þ 0.964
– 4000–8000 3.42 (1.52–7.67) þþ 2.8 104 3.83 (1.90–7.74) þþþ 1.8 104
– 8000 1.77 (0.18–17.60) þ 0.627 1.82 (0.40–8.34) þþ 0.442
SNP*CED: 0 1 (ref) 0.016 1 (ref) 0.018
– >0–4000 3.27 (1.11–9.66) þ 0.032 1.37 (0.29–6.51) þ 0.690
– 4000–8000 1.04 (0.44–2.48) þ 0.922 0.98 (0.48–2.02) þ 0.960
– 8000 3.63 (1.66–7.95) þþ 1.3 103 3.81 (1.85–7.86) þþþ 3.0 104
FANCI rs1054875 A>T 2 rs1054875 1.01 (0.65–1.56) þ 0.977 0.85 (0.57–1.28) þ 0.432
CED: 0 1 (ref) 0.002 1 (ref) 2.0 104
– >0–4000 0.88 (0.28–2.80) þ 0.828 0.54 (0.23–1.24) þ 0.148
– 4000–8000 5.29 (2.08–13.50) þþ 4.7 104 3.91 (1.83–8.33) þþþ 4.1 104
– 8000 3.69 (0.37–36.8) þþ 0.266 3.70 (0.83–16.6) þþþ 0.088
SNP*CED: 0 1 (ref) 0.869 1 (ref) 0.146
– >0–4000 1.35 (0.46–3.96) þþ 0.583 2.76 (1.17–6.53) þþþ 0.021
– 4000–8000 0.64 (0.29–1.40)  0.264 0.92 (0.46–1.86) þ 0.823
– 8000 1.03 (0.53–2.03) þþ 0.925 1.14 (0.61–2.12) þþþ 0.691
PCL, PanCareLIFE cohort; SJLIFE, St. Jude Lifetime Cohort.
Model 2: adjusted for principal components, hormone use (only for VEVO, SJLIFE) and CEDcategories and the interaction term of variant*CED category. þ ¼ positive association of
the SNP with reduced ovarian function in PCL and SJLIFE respectively.  ¼ negative association of the SNP with reduced ovarian function in VEVO, PCL and SJLIFE, respectively.
............................................................................................................................................................................................................................
Table V OR per genotype of rs11668344 (BRSK1) and CED score on reduced ovarian function, based on prevalence in three
cohorts.
genotype AA genotype AG genotype GG
CED in mg/m2 n (%) OR (95% CI) n (%) OR (95% CI) n (%) OR (95% CI)
0 51 (40.8) 1 (ref) 36 (40.0) 0.97 (0.63–1.48) 14 (31.8) 0.68 (0.35–1.30)
>0–4000 19 (37.3) 0.86 (0.48–1.53) 19 (38.8) 0.92 (0.51–1.64) 5 (29.4) 0.60 (0.20–1.82)
4000–8000 36 (69.2) 3.26 (1.95–5.46) 36 (66.7) 3.48 (2.07–5.87) 7 (43.8) 1.13 (0.41–3.14)
8000 43 (58.1) 2.01 (1.31–3.08) 62 (77.5) 5.00 (3.27–7.63) 18 (81.8) 6.53 (2.36–18.05)
n (%) represents the number of cases with reduced ovarian function (% of total) within each genotype group. OR (95% CI) calculated based on the prevalence of a reduced ovarian
function for every genotype and every CED category compared to the prevalence of a reduced ovarian function for survivors with a AA genotype treated without alkylating agents.



































































































increased risk of reduced fertility or a shorter reproductive window.
However, while low AMH levels can also identify poor responders in
assisted reproductive technology (Iliodromiti et al., 2015; van Tilborg
et al., 2017), it needs to be emphasized that AMH remains a surrogate
marker of ovarian function. The implications of low AMH on natural
fertility and reproductive lifespan are under continuing debate. While
in the general population AMH has proven to be a valuable predictor
of menopause, apart from age (van Disseldorp et al., 2008; Tehrani
et al., 2011; Freeman et al., 2012; Dolleman et al., 2013; Depmann
et al., 2016b), current prediction models have not been designed to
predict the extremes of menopausal age (Depmann et al., 2016a,b).
Validation using data collected long-term and using more definite and
direct endpoints such as age at menopause, POI, or fecundity is
needed to facilitate translation into clinical practice. In addition, larger
cohorts would benefit the power of statistical tests.
In conclusion, this study presents data suggesting that high dose alky-
lating chemotherapy-induced reduced ovarian function in female CCS
is strongly modified by a common DNA variant (rs11668344) of the
BRSK1 gene. This is the first time a genetic risk factor has been de-
scribed to modify the effect of chemotherapy on long-term ovarian
function in three independent cohorts. This finding may serve as a
starting point for further research working towards individualized
counselling regarding treatment-related risks and fertility preservation
services in children with cancer as well as young adult survivors.
Supplementary data
Supplementary data are available at Human Reproduction online.
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Figure 1. Simplified representation of the hypothesized
biological plausibility of the effect of BRSK1 on reduced
ovarian function. DNA damage can be the result of environmental
exposure, DNA replication errors but also of chemical exposure.
Alkylating agents are known to induce apoptosis of cancer cells by
damaging DNA and inhibiting cellular metabolism and DNA replica-
tion and transcription (Guainazzi and Schärer, 2010; Kondo et al.,
2010; Fu et al., 2012). DNA damage response genes (BRSK1 is
known to act as a DNA damage checkpoint) have previously been
associated with age at natural menopause. Due to a less efficient
DNA damage response system, childhood cancer patients carrying
the G allele of rs11668344 (BRSK1) may be at an increased risk of
the DNA-damaging impact of alkylating agents.
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Universitätsmedizin Berlin, Germany (Professor A. Borgmann-Staudt,
Mr R. Schilling), Helios Kliniken Berlin-Buch (Dr G. Strauß),
Westfälische Wilhelms-Universität Münster, Germany (Professor A am
Zehnhoff-Dinnesen, Professor U. Dirksen), University Hospital Essen
(Professor U. Dirksen), Universität Bern, Switzerland (Professor C.E.
Kuehni), IRCCS Istituto Giannina Gaslini, Genoa, Italy (Dr R. Haupt, Dr
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